MPLT
MapLight TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The bull case is that MPLT has two meaningful Phase 2 readouts arriving in the same mid-August 2026 window, with prior company updates showing enrollment completion in ZEPHYR and completion of the last patient visit in IRIS, while cash runway through 2027 lowers near-term financing overhang [#SEC-8K-2026-05-14].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.4.
What can break
Binary clinical-readout risk is the dominant risk, with both ZEPHYR and IRIS expected around mid-August 2026.
Momentum
96
Value
46
Sentiment
24
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $38.00 · Bear $21.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $41.85
Why
Momentum96 · Δ7d -0.4
Value46 · Δ7d +0.0
Sentiment24 · Δ7d +0.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
+6.3
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
24
34% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
-11.7
Why this grade
Composite grade C. Momentum 96.4 / Value 46.4 / Sentiment 24.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.53B
Beta
-
Shares Out
42.62M
P/E (TTM) · Derived
-9.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.66
Rev YoY
-
EPS YoY
+172.5%
Gross Margin
-
Op Margin
-
Net Debt
-$299.3M
Current Ratio
22.91
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology